Statement
-
Statement
Incubate submits comment to CMS regarding its draft guidance for the Medicare Drug Price Negotiation Program
04.17.2023
Incubate submitted our feedback to the Centers for Medicare & Medicaid Services regarding its draft guidance for the Medicare Drug Price Negotiation Program.
-
Statement
In Rejecting “March-In Rights” Petition for Xtandi, NIH Sends a Strong Message in Support of Intellectual Property Protections
03.31.2023
Earlier this week, the National Institutes of Health rejected a petition to initiate “march-in” proceedings.
-
Statement
Incubate Testifies at USITC Hearing
03.31.2023
Executive Director John Stanford testified before the International Trade Organization.
-
Statement
Life Science Venture Capital Responds to President Biden’s FY24 Budget
03.09.2023
Today, March 9th, 2023, President Biden released his Fiscal Year (FY) 2024 proposed budget and recommendations. Notably, one proposal indicates that the President seeks to expand price controls established in the Inflation Reduction Act of 2022.
-
Statement
Life Science Venture Capital Responds to President Biden’s State of the Union
02.08.2023
We must bolster the scientific biopharmaceutical ecosystem, not abandon it.
-
Statement
Incubate Statement on Amendment 5284 of the Inflation Reduction Act
08.06.2022
Incubate issued the following statement in response to amendment 5284 of the Inflation Reduction Act:
-
Statement
Incubate Letter on Reconciliation Drug Pricing Provisions
07.15.2022
Read Incubate's letter to the US Senate on their recent drug price provisions in the Reconciliation package
-
Statement
Incubate Statement on Federal Drug Price Provisions
07.06.2022
See Incubate's statement in response to the recent Reconciliation bill text on drug price controls.
-
Statement
Incubate Statement on WTO Decision to Suspend Global IP Rights
06.30.2022
The Incubate Coalition issued the following statement preceding the WTO TRIPS Council meeting (July 6-7) and following the World Trade Organization’s decision at its 12th Ministerial Conference in Geneva, Switzerland to waive intellectual property (IP) protections for Covid-19 vaccines.
-
Statement
Incubate Comment in Response to the FTC’s Request for Comments on the Business Practices of PBMs
05.25.2022
Read Incubate's response to the FTC's Solicitation for Public Comments on the Business Practices of Pharmacy Benefit Managers and Their Impact on Independent Pharmacies and Consumers
-
Statement
Incubate Executive Director John Stanford Statement in Response to the Centers for Medicare & Medicaid Services’ Devastating Final National Coverage Determination for Certain Alzheimer’s Treatments
04.14.2022
See Executive Director John Stanford's statement on CMS' Final NCD on Alzheimer's disease and how this will affect the future of biopharmaceutical investment.